Conference Day One

Wednesday 18th October 2023

8:00 am Coffee & Registration

8:50 am Chair’s Opening Remarks

Bringing the Next Wave of Innate Immunotherapies to Market

9:00 am FIRESIDE DISCUSSION: Harnessing the Innate Immune Sytem to Bring Efficacious Immunotherapies to Patients in Need

  • Evren Alici Group leader, Cell and Gene Therapy, Karolinska Institutet
  • Robert Igarashi Head of Discovery, Kiadis, a Sanofi Company


  • Where are we now and what are the most pressing challenges preventing innate immune therapies from getting to clinic?
  • What are the big breakthroughs that we're seeing in this space?
  • How do we address pipeline progression challenges?
  • How is the investment landscape affecting Innate Killer Cell Therapy development?
  • What does the future of this field need to achieve?

9:30 am PANEL DISCUSSION: Anticipating Key CMC Regulatory Challenges to Shorten Innate Cell Therapy Approval Pathways to Market


With the industry primed to enter the clinic with a variety of next generation innate cell therapies, attention turns to achieving a commercially viable drug product through CMC regulatory clarity to provide effective scale up.

Appreciating key CMC challenges for an effective and efficient scale up of innate cell therapies

Understanding the importance of engaging regulators as early as possible to defining specifications and acceptance criteria for a timely drug product release

  • Elucidating karyotyping requirements for genetically engineered innate cell therapy products
  • Revealing regulatory views on donor batch variability throughout the manufacturing process to achieve a successfully scaled allogenic innate cell therapy

10:00 am Morning Refreshment Break & Speed Networking

Utilising the Innate Immune System to Overcome Tumour Resistance Mechanisms & Facilitate a wider Immune Response

11:00 am ADAPT-NK –an allogeneic adaptive NK cell therapy platform to unleash NK cell potential


  • Leveraging adaptive NK cell properties to circumvent inhibitory hurdles of NK cell therapies
  • Utilizing highly cytotoxic ADAPT-NK cells against liquid and solid tumor targets, and in combination with engages
  • Establishment of manufacturing protocol and cell banks to support dose-escalation and expansion of Phase I/II studies

11:30 am Case Study: Boosting NK Cells through Cytokine Conditioning: Promoting Ex Vivo Proliferative Capacity & Resistance to Immune Suppression in the TME

  • Andre Kunert Senior Principal Scientist, Kiadis, a Sanofi Company


  • Utilising cytokines to drive proliferative capacity of NK cells
  • Leveraging stimulatory and inhibitory signalling to condition NK cells for increased cytotoxic capacity
  • Overcoming immune suppression and shaping the TME through altered signalling and cytokine release

12:00 pm Case Study: Leveraging Dendritic Cell Biology to Improve NK-cell Based Therapeutic Approaches


  • Dendritic cell biology can be used to improve NK-cell based therapeutic approaches
  • Intratumoral allogeneic dendritic cells activate NK cells and broader antitumour immune responses
  • Leukemic-derived dendritic cells can be used to expand memory NK cells for therapeutic purposes

12:30 pm Case Study: Clinical Gamma-Delta T-Cell Therapies, Demonstrating Persistence & Durability for Positive Outcomes in Hematological & Solid Tumours


  • The first clinical data on gamma-delta T-cell therapies demonstrating persistence, durability and expansion in patients
  • Leveraging gamma-delta T-cell properties to evade the endogenous immune response
  • Intelligent engineering to maximise the tumor targeting ability of gamma-delta T-cells to bring cell therapies into solid tumours

1:00 pm Case Study: Allogeneic Invariant Natural Killer T-Cells: Approaches for Solid Tumor Treatment

  • Marco Purbhoo Director, Translational Research, MiNK Therapeutics


  • Why iNKT cells are a highly effective and efficient platform for allogeneic cell therapy
  • Which approaches does MiNK Therapeutics pursue for the development of solid tumor therapy?
  • Recent MiNK preclinical and clinical data on ongoing programs

1:30 pm Networking Lunch

Reconsidering Innate Cell Scarcity & Phenotypic Complexity to Promote an Effective & Efficient Engraftment Strategy

2:30 pm Session Reserved for Miltenyi Biotech

3:00 pm ROUNDTABLE DISCUSSION: Building Industry Synchronisation for a High- Quality Engraftment Strategy

  • Evren Alici Group leader, Cell and Gene Therapy, Karolinska Institutet


With the innate cell therapy industry utilising iPSCs in addition to cord and peripherally-derived innate cells for therapeutic use, the need for engraftment synchronisation has never been more important for leaders in this dynamic space. This roundtable provides an opportunity for industry leaders to state their views on aspects of engraftment and discuss key topics such as patient conditioning and material characterisation to help understand ways to elevate a safe and effective engraftment strategy.

4:00 pm Innovator’s Poster Session

Evaluating the Role of Genetic Engineering to Reduce Immunogenicity & Increase Persistence of Innate Cell Therapies

5:00 pm Case Study: Harnessing Autologous NK Cells for Personalised Immunotherapy


  • Engineering vs non-engineering strategies
  • Important aspects of repeat dosing
  • Strategies to increase cell potency, targeting and persistence

5:30 pm Case Study: Next Generation Engineering Platforms to Enhance Adoptive NK Cell Therapies

  • Rafet Basar Assistant Professor, MD Anderson Cancer Center


  • Improving the specificity, persistence, and antitumour activity of NK cells by engineering them with CAR
  • Precision genome editing of NK or CAR NK cells using CRISPR-cas9 technology to enhance their potency and circumvent tumour induced immunosuppression
  • Arming NK cells or CAR NK cells with antibodies to improve their cytolytic activity and allow multi-targeting

6:00 pm Chair’s Closing Remarks

6:10 pm End of Day 1